

## EQA round: APLA2/17 - Antiphospholipid Antibodies

Dead line: 03.11.2017

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

## Test

Sample	Group		N	Result	N <sub>rel</sub>
<b>(461) anti-cardiolipin screening</b>					
A	(38) IL	>>>	1	Negative	5,9 %
	(135) OrgenTec	>>>	9	Negative	53 %
	(139) BL Diagnostics	>>>	3	Negative	18 %
	(148) Aesku.lab Diagnostika	>>>	4	Negative	24 %
Total per sample: n = 17		Success: 100 %			
B	(38) IL	>>>	1	Positive	5,9 %
	(135) OrgenTec	>>>	9	Positive	53 %
	(139) BL Diagnostics	>>>	3	Positive	18 %
	(148) Aesku.lab Diagnostika	>>>	4	Positive	24 %
Total per sample: n = 17		Success: 100 %			
Total success: 100 %					

**(463) anti-cardiolipin IgG**

A	(5) Dialab	>>>	1	Negative	1,9 %
	(32) Human	>>>	1	Negative	1,9 %
	(38) IL	>>>	2	Negative	3,8 %
	(87) Euroimmun	>>>	2	Negative	3,8 %
	(115) BioSystems	>>>	2	Negative	3,8 %
	(135) OrgenTec	>>>	23	Negative	44 %
			1	Positive	1,9 %
	(139) BL Diagnostics	>>>	5	Negative	9,6 %
	(147) AIDA	>>>	1	Negative	1,9 %
	(148) Aesku.lab Diagnostika	>>>	6	Negative	12 %
	(211) INOVA Diagnostics	>>>	2	Negative	3,8 %
	(999) another manufacturer	>>>	6	Negative	12 %
Total per sample: n = 52		Success: 98 %			
B	(5) Dialab	>>>	1	Positive	1,9 %
	(32) Human	>>>	1	Positive	1,9 %
	(38) IL	>>>	2	Positive	3,8 %
	(87) Euroimmun	>>>	2	Positive	3,8 %
	(115) BioSystems	>>>	2	Positive	3,8 %
	(135) OrgenTec	>>>	1	Negative	1,9 %
		>>>	23	Positive	44 %
	(139) BL Diagnostics	>>>	5	Positive	9,6 %
	(147) AIDA	>>>	1	Positive	1,9 %
	(148) Aesku.lab Diagnostika	>>>	6	Positive	12 %
	(211) INOVA Diagnostics	>>>	2	Positive	3,8 %
	(999) another manufacturer	>>>	6	Positive	12 %
Total per sample: n = 52		Success: 98 %			
Total success: 98 %					

**(464) anti-cardiolipin IgM**

A	(5) Dialab	>>>	1	Negative	2,0 %
	(32) Human	>>>	1	Negative	2,0 %
	(38) IL	>>>	2	Negative	3,9 %
	(87) Euroimmun	>>>	2	Negative	3,9 %
	(115) BioSystems	>>>	2	Negative	3,9 %
	(135) OrgenTec	>>>	23	Negative	45 %
	(139) BL Diagnostics	>>>	5	Negative	9,8 %
	(147) AIDA	>>>	1	Negative	2,0 %
	(148) Aesku.lab Diagnostika	>>>	6	Negative	12 %
	(211) INOVA Diagnostics	>>>	2	Negative	3,9 %
	(999) another manufacturer	>>>	6	Negative	12 %
Total per sample: n = 51		Success: 100 %			
B	(5) Dialab	>>>	1	Negative	2,0 %
	(32) Human	>>>	1	Negative	2,0 %
	(38) IL	>>>	2	Negative	3,9 %
	(87) Euroimmun	>>>	2	Negative	3,9 %
	(115) BioSystems	>>>	2	Negative	3,9 %
	(135) OrgenTec	>>>	20	Negative	39 %
			1	Inconclusive result (borderline)	2,0 %
			2	Positive	3,9 %
	(139) BL Diagnostics	>>>	2	Negative	3,9 %
			3	Inconclusive result (borderline)	5,9 %
	(147) AIDA	>>>	1	Negative	2,0 %
	(148) Aesku.lab Diagnostika	>>>	6	Negative	12 %

## EQA round: APLA2/17 - Antiphospholipid Antibodies

Dead line: 03.11.2017

Test			N	Result	N <sub>rel</sub>
Sample	Group				
B	(211) INOVA Diagnostics	>>>	2	Negative	3,9 %
	(999) another manufacturer	>>>	6	Negative	12 %
Total per sample: n = 51		Success: 88 %			
Total success: 88 %					

**(465) anti-beta2-GP 1 screening**

A	(5) Dialab	>>>	2	Negative	17 %
	(38) IL	>>>	1	Negative	8,3 %
	(135) OrgenTec	>>>	5	Negative	42 %
	(139) BL Diagnostics	>>>	2	Negative	17 %
	(148) Aesku.lab Diagnostika	>>>	2	Negative	17 %
Total per sample: n = 12		Success: 100 %			
B	(5) Dialab	>>>	2	Positive	17 %
	(38) IL	>>>	1	Positive	8,3 %
	(135) OrgenTec	>>>	5	Positive	42 %
	(139) BL Diagnostics	>>>	2	Positive	17 %
	(148) Aesku.lab Diagnostika	>>>	2	Positive	17 %
Total per sample: n = 12		Success: 100 %			
Total success: 100 %					

**(467) anti-beta2-GP 1 IgG**

A	(32) Human	>>>	1	Negative	2,1 %
	(38) IL	>>>	2	Negative	4,2 %
	(87) Euroimmun	>>>	2	Negative	4,2 %
	(115) BioSystems	>>>	2	Negative	4,2 %
	(135) OrgenTec	>>>	26	Negative	54 %
			1	Positive	2,1 %
	(139) BL Diagnostics	>>>	5	Negative	10 %
	(147) AIDA	>>>	1	Negative	2,1 %
	(148) Aesku.lab Diagnostika	>>>	3	Negative	6,3 %
	(211) INOVA Diagnostics	>>>	2	Negative	4,2 %
	(999) another manufacturer	>>>	3	Negative	6,3 %
Total per sample: n = 48		Success: 98 %			
B	(32) Human	>>>	1	Positive	2,1 %
	(38) IL	>>>	2	Positive	4,2 %
	(87) Euroimmun	>>>	2	Positive	4,2 %
	(115) BioSystems	>>>	2	Positive	4,2 %
	(135) OrgenTec		1	Negative	2,1 %
			1	Inconclusive result (borderline)	2,1 %
		>>>	25	Positive	52 %
	(139) BL Diagnostics	>>>	5	Positive	10 %
	(147) AIDA	>>>	1	Positive	2,1 %
	(148) Aesku.lab Diagnostika	>>>	3	Positive	6,3 %
	(211) INOVA Diagnostics	>>>	2	Positive	4,2 %
	(999) another manufacturer	>>>	3	Positive	6,3 %
Total per sample: n = 48		Success: 96 %			
Total success: 96 %					

**(468) anti-beta2-GP 1 IgM**

A	(32) Human	>>>	1	Negative	2,1 %
	(38) IL	>>>	2	Negative	4,3 %
	(87) Euroimmun	>>>	1	Negative	2,1 %
	(115) BioSystems	>>>	2	Negative	4,3 %
	(135) OrgenTec	>>>	27	Negative	57 %
	(139) BL Diagnostics	>>>	6	Negative	13 %
	(147) AIDA	>>>	1	Negative	2,1 %
	(148) Aesku.lab Diagnostika	>>>	3	Negative	6,4 %
	(211) INOVA Diagnostics	>>>	2	Negative	4,3 %
	(999) another manufacturer	>>>	2	Negative	4,3 %
Total per sample: n = 47		Success: 100 %			
B	(32) Human	>>>	1	Negative	2,1 %
	(38) IL	>>>	1	Inconclusive result (borderline)	2,1 %
		>	1	Positive	2,1 %
	(87) Euroimmun	>	1	Positive	2,1 %
	(115) BioSystems	>>>	1	Negative	2,1 %
		>>>	1	Inconclusive result (borderline)	2,1 %
	(135) OrgenTec	>>>	20	Negative	43 %
		>>>	4	Inconclusive result (borderline)	8,5 %
		>	3	Positive	6,4 %
	(139) BL Diagnostics	>>>	1	Negative	2,1 %
		>>>	3	Inconclusive result (borderline)	6,4 %

**Summary statistics - qualitative results**

(Groups: manufacturer of kit)

**EQA round: APLA2/17 - Antiphospholipid Antibodies**

Dead line: 03.11.2017

**Test**

Sample	Group	N	Result	N <sub>rel</sub>
B	(139) BL Diagnostics	>	2 Positive	4,3 %
	(147) AIDA	>>>	1 Negative	2,1 %
	(148) Aesku.lab Diagnostika	>>>	3 Negative	6,4 %
	(211) INOVA Diagnostics	>>>	1 Negative	2,1 %
	(999) another manufacturer	>>>	1 Inconclusive result (borderline)	2,1 %
		>>>	2 Negative	4,3 %
----- Total per sample: n = 47 -----		Success: 100 %		

Total success: 100 %

st\_kl

End of report

Printed: 11.11.2017